1. Scrip
  2. >>R&D
  3. >>Trial Results

Tackling Acute Gastroenteritis: RedHill Biopharma's Bekinda A Novel Approach?

 
• By John Davis
  
Generate a summary of this article
Listen to this article
Beta

A new long-acting ondansetron product that reduces nausea and vomiting during acute viral gastroenteritis, whatever the type of virus involved and for long periods of time, could change the way emergency physicians respond to gastroenteritis outbreaks, and is underpinning the specialty pharma business strategy of RedHill Biopharma.

Gastroenteritis
• Source: Shutterstock

The development of a long-acting ondansetron formulation, RedHill Biopharma Ltd.’s Bekinda 24 mg once-daily extended-release tablets, for gastroenteritis, could change the way healthcare professionals deal with norovirus and other debilitating but self-limiting infectious gastroenteritis outbreaks, that are associated with high rates of emergency room admissions, and re-admissions.

RedHill BioPharma, an emerging US/Israeli specialty pharmaceutical company, has just released positive top-line results from the Phase III GUARD study...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D